









Humber Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on November 2023

Classification of products:

Status	Description
 GREEN	Medicines suitable for routine use within primary care and Secondary care. May be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies
 AMB 1	Specialist recommendation: These medicines are considered suitable for GP prescribing following specialist recommendation or via an APC approved prescribing guideline.
 AMB 2	Specialist initiation: These medicines are considered suitable for GP prescribing following specialist initiation, including titration of dose and assessment of efficacy. These medicines may also have an APC approved guideline to aid GPs in further prescribing.
 AMB SCP	AMBER SHARE CARE PROTOCOL- Specialist initiation with ongoing monitoring: Medicines that must be initiated by a specialist, and which require significant monitoring on an ongoing basis. Full agreement to share the care of each specific patient must be reached under the shared care protocol which must be provided to the GP. If a commissioned shared care is not available in CCG/place then these drugs must be treated as red drug (hospital only).
 RED	Red-Hospital initiation and continuation only
 GREY	GREY- NON FORMULARY (As agreed by Area Prescribing Committee)
 PURPLE	To be supplied from the appropriate commissioned provider.
 NR	Not routinely commissioned

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
1) Requests deferred from previous meetings				
Nil this month				
2) New Requests				
Difelikefalin	RED			TA890- HUTH
Letermovir	RED			HUTH
Ibuprofen IV	RED			NLaG
Benzobromarone	RED			NLaG- Unlicensed list
3) New formulations & extensions to use				

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
Nil this month				
4) Products considered by NICE				
TA913: Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA914: Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
5) Appeals against earlier decisions by the APC				
None				
6) Miscellaneous formulary decisions by the APC				
Nil this month				

The following guidelines were presented to and approved at the November 2023 meeting of the APC:

- Amber Guidance Migraine (update)

The following Drug information leaflets were presented to and approved at the November 2023 meeting of the APC:

- Nil this month

The following shared care guidelines were presented to and approved at the November 2023 meeting of the APC:

- Nil this month

Other documents presented to and approved at the September 2023 meeting of the APC:

- Blood Glucose Formulary (minor update)
- Specialist Infant Formulae (minor update)